HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC
Clinical trials for HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC explained in plain language.
Never miss a new study
Get alerted when new HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC trials appear
Sign up with your email to follow new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New cocktail of cancer drugs shows promise for tough head and neck tumors
Disease control OngoingThis early-stage study tests whether combining several drugs can shrink tumors in adults with head and neck cancer that didn't respond to previous treatments. Participants receive up to three antibodies: two that help the immune system fight cancer, one that blocks tumor growth s…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated May 17, 2026 09:23 UTC
-
Immunotherapy plus precision radiation shows promise against returning head and neck cancer
Disease control OngoingThis study tests whether adding the immunotherapy drug pembrolizumab (Keytruda) to targeted radiation (SBRT) can help people with head and neck cancer that has returned or is a new tumor in the same area. About 86 adults whose cancer cannot be removed by surgery will be randomly …
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC
Phase: PHASE2 • Sponsor: RTOG Foundation, Inc. • Aim: Disease control
Last updated May 17, 2026 09:22 UTC
-
New drug cocktail shows promise in shrinking head and neck tumors before surgery
Disease control OngoingThis study tests whether adding another immune-boosting drug (relatlimab or ipilimumab) to the standard immunotherapy nivolumab can better shrink head and neck tumors before surgery. About 80 adults with advanced but removable head and neck cancer will receive one of these combin…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC
Phase: PHASE2 • Sponsor: Dan Zandberg • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New cancer drug AB598 enters early human safety testing
Disease control OngoingThis early-phase study tests the safety of a new drug called AB598, given alone or with other treatments, in about 40 people with advanced solid tumors (e.g., lung, bladder, breast, or ovarian cancer). The main goal is to see if the drug is safe and tolerable. Participants must h…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC
Phase: PHASE1 • Sponsor: Arcus Biosciences, Inc. • Aim: Disease control
Last updated May 13, 2026 16:03 UTC
-
New combo therapy aims to shrink tough head and neck tumors
Disease control OngoingThis study tests whether adding an experimental drug (INBRX-106) to a standard immunotherapy (pembrolizumab) works better than the standard drug alone for people with advanced head and neck cancer that has spread or come back. About 410 adults whose tumors have a specific marker …
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC
Phase: PHASE2, PHASE3 • Sponsor: Inhibrx Biosciences, Inc • Aim: Disease control
Last updated May 11, 2026 20:48 UTC
-
New antibody combo shows promise against tough cancers
Disease control OngoingThis study tests an experimental antibody called GEN1042, alone or with the cancer drug pembrolizumab (with or without chemotherapy), in people with advanced solid tumors like lung, colon, melanoma, head and neck, or pancreatic cancer. The goal is to see if the treatment is safe …
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC
Phase: PHASE1, PHASE2 • Sponsor: Genmab • Aim: Disease control
Last updated May 07, 2026 18:38 UTC
-
Scientists hunt for clues to predict immunotherapy success in head and neck cancer
Knowledge-focused OngoingThis study aims to find immune system markers that can predict how well the drug nivolumab works in people with recurrent or metastatic head and neck squamous cell carcinoma. Researchers will analyze tumor tissue and blood samples from 50 participants to look for these markers. T…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC
Phase: NA • Sponsor: Yonsei University • Aim: Knowledge-focused
Last updated May 14, 2026 12:04 UTC